Product Description
Amoxicillin is used to treat certain infections caused by bacteria, such as pneumonia; bronchitis (infection of the airway tubes leading to the lungs); and infections of the ears, nose, throat, urinary tract, and skin. It is also used in combination with other medications to eliminate H. pylori, a bacteria that causes ulcers. Amoxicillin is in a class of medications called penicillin-like antibiotics. It works by stopping the growth of bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a685001.html)
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Benin, Canada, China, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Kenya, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Serbia, Slovenia, Spain, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 11
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: COVID-19|Fractures, Open|Influenza, Human|Pneumonia|Respiratory Tract Infections|Urinary Tract Infections
Phase 2: Buruli Ulcer|Diverticulitis
Phase 1: Abscess|Bronchitis|Bronchitis, Chronic|Cellulitis|Community-Acquired Infections|Cystitis|Escherichia coli Infections|Haemophilus Infections|Helicobacter Infections|Osteomyelitis|Other|Otitis Media|Pharyngitis|Pneumonia, Bacterial|Proteus Infections|Pyelonephritis|Short Bowel Syndrome|Sinusitis|Soft Tissue Infections|Tonsillitis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05584683 |
LP-001 | P1 |
Completed |
Other |
2024-12-16 |
12% |
2025-02-06 |
Primary Endpoints |
CTR20253270 |
CTR20253270 | P1 |
Completed |
Sinusitis|Bronchitis|Otitis Media|Proteus Infections|Helicobacter Infections|Escherichia coli Infections|Tonsillitis|Pneumonia|Soft Tissue Infections|Respiratory Tract Infections|Influenza, Human|Haemophilus Infections|Pharyngitis |
2025-10-14 |
2025-11-16 |
||
NCT05302531 |
GRAAL | P1 |
Recruiting |
Short Bowel Syndrome |
2024-12-01 |
50% |
2024-11-27 |
Primary Endpoints|Treatments |
CTR20241408 |
CTR20241408 | P1 |
Completed |
Urinary Tract Infections|Cystitis|Pneumonia, Bacterial|Otitis Media|Soft Tissue Infections|Cellulitis|Community-Acquired Infections|Sinusitis|Abscess|Osteomyelitis|Respiratory Tract Infections|Bronchitis, Chronic|Pyelonephritis |
2024-07-09 |
2025-08-24 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
2023-506224-87-00 |
DIREBIOT | P2 |
Recruiting |
Diverticulitis |
2025-12-31 |
2025-05-02 |
Treatments |
|
2023-508442-18-00 |
DURATIOM | P3 |
Not yet recruiting |
Fractures, Open |
2027-12-31 |
2025-05-02 |
Treatments |
|
NCT02735707 |
REMAP-CAP | P3 |
Recruiting |
Influenza, Human|Pneumonia|COVID-19 |
2026-02-01 |
2024-11-27 |
||
NCT05169554 |
BLMs4BU | P2 |
Recruiting |
Buruli Ulcer |
2026-05-31 |
12% |
2024-05-17 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
CTR20230643 |
CTR20230643 | P1 |
Completed |
Helicobacter Infections |
2023-04-28 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT04041791 |
SEARCH | P3 |
Completed |
Pneumonia |
2024-04-05 |
2024-05-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
|
CTR20131000 |
CTR20131000 | P3 |
Recruiting |
Urinary Tract Infections|Respiratory Tract Infections |
None |
2025-04-29 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/07/2026 |
News Article |
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results |
|
01/07/2026 |
News Article |
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants |
|
01/05/2026 |
News Article |
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects |
|
12/11/2025 |
News Article |
FDA Approves USAntibiotics' Augmentin XR in Historic First for Expedited Review Program |